Thu.Nov 21, 2024

article thumbnail

After youth vaping surge, the U.K. moves to ban disposable e-cigarettes

STAT

LONDON — The stacks of brightly colored disposable e-cigarettes, touting flavors like cotton candy ice and greengrape melon and often looming over the not-dissimilar-looking candy displays, have become a commonplace sight in convenience stores in both the U.S. and the U.K.  But here, they’re on their way out.

307
307
article thumbnail

Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals

PharmaVoice

A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.

290
290
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment

STAT

Novartis said Thursday it purchased gene therapy startup Kate Therapeutics for up to $1.1 billion in upfront payments and milestones.  It’s a rare buyout for a field that has quieted over the last couple years, amid a wider biotech downturn and questions about both the effectiveness and profitability of these one-time treatments.  With the deal, Novartis will acquire a pipeline of preclinical gene therapies for three different genetic neuromuscular diseases, along with the under

272
272
article thumbnail

Pfizer, under pressure to change, names oncology head as new R&D chief

PharmaVoice

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

113
113
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Opinion: It took years for my Black son to be diagnosed with cystic fibrosis. Then it happened to my family again

STAT

Twenty years ago, cystic fibrosis wasn’t a household term for me. Today, cystic fibrosis — a genetic disorder that causes a buildup of thick, sticky mucus that can damage organs, especially the lungs — has become a centerpiece of my family’s lives, sending me on an advocacy mission to improve diagnosis and care for all families, regardless of their racial or ethnic background.

288
288
article thumbnail

Lupin receives FDA approval for generic version of Adderall XR

Express Pharma

On 19 November 2024, Lupin announced that it had received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules. The approval covers dosage strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg, which are the generic equivalent of Adderall XR Extended-Release Capsules marketed by Takeda Ph

Dosage 100

More Trending

article thumbnail

360 ONE Asset acquires stake in OneSource

Express Pharma

360 ONE Asset announced an investment in OneSource Specialty Pharma, a pharma CDMO in India. 360 ONE Asset is acquiring a stake from an existing investor. OneSource is a player in biologics, drug-device combinations, complex injectables, and soft gelatin capsules. OneSource has the expertise to develop and manufacture complex products such as GLP-1 drugs and novel biologics.

85
article thumbnail

STAT+: The state of biotech M&A 2024

STAT

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Biotech M&A has been disappointing. Perhaps the trend will improve before we reach the holidays, but I can only opine on what’s transpired, and honestly, that’s not much.

268
268
article thumbnail

Solution Spotlight: Within3

pharmaphorum

Discover how Within3's community-driven platform helps businesses gather and utilise data effectively. Explore our solution spotlight for insights into their innovative approach.

87
article thumbnail

Versant enters obesity with new startup

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hullo! Today, some squiddy drug delivery, a leukemia deal between Kura Oncology and Kyowa Kiri, and a new GLP-1 startup from Versant Ventures.

article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Your Guide to EGCG (Epigallocatechin-3-gallate)

Compounding Pharmacy of America

Recently, a compound known as EGCG has emerged as a leading weight loss supplement. This new supplement offers hope for many people struggling with myriad health issues, including obesity. However, weight loss isn’t the only benefit to this amazing supplement. The post Your Guide to EGCG (Epigallocatechin-3-gallate) appeared first on The Compounding Pharmacy of America.

article thumbnail

Squid-inspired replacements for needles; Science Twitter and Bluesky

STAT

Good morning, I’m back! And I can barely believe all the news that happened while I was away. On vacation, my biggest concern was a broken milkshake machine at a highway McDonald’s. Why are they always broken?? (Addendum: Editors know things! Mine just sent me this story in the Verge about an update to the “right to repair” issues that have long plagued McDonald’s franchise owners and their machines.

256
256
article thumbnail

Biotech startups are built on venture capital. Track funding rounds here.

BioPharma Dive

Venture capital firms incubate, grow and finance dozens of new drug companies each year. Follow the money they channel into the industry with this database.

109
109
article thumbnail

FDA chief: AI adoption driven by financial reasons, not patient benefits

STAT

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. Robert Califf: Clinical care should drive AI adoption It’s day two of the FDA’s advisory committee meeting on regulating generative artificial intelligence tools.

173
173
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Pharmacy First won't tempt practice pharmacists back into community yet, survey suggests

The Pharmacist

EXCLUSIVE Expanding clinical opportunities in community pharmacy are not enough to make pharmacists working in GP surgeries want to reconsider a career in the sector, our snapshot survey has suggested. Practice pharmacist respondents cited reasons including increased workload with fewer resources, a lack of structures and support in place, and a lack of opportunity to […] The post Pharmacy First won't tempt practice pharmacists back into community yet, survey suggests appeared first o

article thumbnail

Novartis raises mid-term sales outlook on pipeline promise

pharmaphorum

Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets

94
article thumbnail

Kura Oncology partners Kyowa Kirin to advance AML treatment

Pharmaceutical Technology

Kura has partnered Kyowa Kirin in a strategic global collaboration for developing and commercialising oral ziftomenib to treat AML

98
article thumbnail

23andMe stock sell-off adds to its woes

pharmaphorum

Shares in genetic testing company 23andMe continue to slide after prominent investors announce plans to sell their stakes.

82
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Amgen picks prolific biotech founder Chang as new top scientist

BioPharma Dive

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.

74
article thumbnail

Eisai debuts biliary tract cancer drug in Japan

pharmaphorum

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug.

71
article thumbnail

Versant startup sets out to make a new type of obesity drug

BioPharma Dive

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a treatment that can improve upon drugs like Wegovy and Zepbound.

74
article thumbnail

McKinsey nears $600m settlement with US government over role in opioid crisis

The Guardian - Pharmaceutical Industry

Consultancy firm accused of helping opioid makers boost sales, which allegedly contributed to deadly epidemic McKinsey is in the final stages of negotiating a deferred prosecution agreement to resolve a US criminal investigation into the consulting firm’s work helping opioid manufacturers boost sales that allegedly contributed to a deadly addiction epidemic , people familiar with the matter said.

77
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Soft launch of first indigenous antibiotic to combat AMR, Nafithromycin, announced by Dr Jitendra Singh

Express Pharma

Union Minister Dr Jitendra Singh formally launched the first indigenous antibiotic “Nafithromycin” for resistant infections. It is only after 2014, when Prime Minister Narendra Modi took over that our researchers received the right kind of support to explore their potential, said Dr Jitendra Singh. The antibiotic Nafithromycin has been developed with the support of the Biotechnology Industry Research Assistance Council (BIRAC), a unit of the Department of Biotechnology and has been brought to ma

article thumbnail

Setting the Correct Medicine Launch Prices: A Comprehensive Guide

Drug Patent Watch

In the complex world of biopharmaceuticals, setting the right price for a new medicine is both an art and a science. It’s a decision that can make or break a product’s success, impacting everything from patient access to long-term profitability. Let’s dive into the intricacies of this crucial process and explore how companies can navigate the challenging waters of medicine launch pricing.

69
article thumbnail

Novartis wagers more than $1B on gene therapies for the nervous system

BioPharma Dive

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like Duchenne muscular dystrophy and myotonic dystrophy type 1.

69
article thumbnail

Draft legislation sets out steps for cutting business rates for pharmacies from 2026

The Pharmacist

The government has published draft legislation outlining a ‘permanent’ cut in business rates for retail, hospitality and leisure (RHL) properties from 2026, including pharmacies. The tax cut will be funded by a tax rise for the very largest business properties, such as online sales warehouses. Until then, 250,000 RHL properties will receive 40% relief off […] The post Draft legislation sets out steps for cutting business rates for pharmacies from 2026 appeared first on The Pharmacist.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Jiangsu Hansoh ADC HS-20093 holds potential to set new standard in SCLC second-line treatment in China: GlobalData

Express Pharma

Jiangsu Hansoh Pharmaceutical Group has recently obtained approval for HS-20093, a B7-H3-targeted antibody-drug conjugate (ADC) to be included as Breakthrough-Therapy-Designated (BTD) Drug by the National Medical Products Administration (NMPA) of China for extensive stage small cell lung cancer (ES-SCLC) after standard first-line treatment. Against this backdrop, HS-20093 is expected to strengthen Jiangsu Hansoh position in the Chinese oncology market, says GlobalData.

article thumbnail

UK CPhOs issue advice to pharmacists on assisted dying debate

The Pharmacist

The UK’s most senior pharmacists have issued advice to those among the pharmacy professions who want to take part in the public debate around assisted dying. Chief pharmaceutical Officers (CPhOs) and other pharmacy leaders said on Wednesday that it is ‘entirely reasonable’ for pharmacists and pharmacist technicians to give their opinions and that ‘the public […] The post UK CPhOs issue advice to pharmacists on assisted dying debate appeared first on The Pharmacist.

65
article thumbnail

Vyvgart Hytrulo gains first APAC approval in China, redefining CIDP care: GlobalData

Express Pharma

China’s National Medical Products Administration (NMPA) approval of Zai Lab and argenx’s Vyvgart Hytrulo (efgartigimod alfa injection) marks a transformative milestone in chronic inflammatory demyelinating polyneuropathy (CIDP) care, offering the first targeted therapy for this debilitating autoimmune disorder. This approval signals a paradigm shift in CIDP management, underscoring innovation’s role in improving patient outcomes, says GlobalData, a leading data and analytics company.

article thumbnail

Less than half of PCNs increased ARRS pay by 5.5%

The Pharmacist

Less than half of primary care networks (PCNs) have given their Additional Roles Reimbursement Scheme (ARRS) staff – such as practice pharmacists and pharmacy technicians – a pay rise of at least 5.5% since April this year, according to a new survey. Of the 129 GPs with a PCN role who responded to the survey […] The post Less than half of PCNs increased ARRS pay by 5.5% appeared first on The Pharmacist.

article thumbnail

Amgen and Pfizer appoint new Science executives

European Pharmaceutical Review

Several new appointments were announced by Amgen and Pfizer yesterday, focusing on R&D functions. Pfizer Inc. is appointing Dr Chris Boshoff , PhD, as Chief Scientific Officer and President, Research & Development. Dr Boshoff will begin this new role on 1 January 2025 and will oversee all R&D functions across every therapeutic area in the company.